Opal Lee returns to Fort Worth after Ohio hospitalization
Opal Lee, the 98-year-old "grandmother of Juneteenth," has returned to Fort Worth after being hospitalized in Ohio.
She's currently resting and not doing interviews, though she did take a call from former Vice President Kamala Harris.
Lee will still participate in her Juneteenth Walk for Freedom on June 19, but will use a golf cart to conserve energy.
FORT WORTH, Texas - Opal Lee, the grandmother of Juneteenth, is back in Fort Worth after being admitted to the hospital in Ohio.
The 98-year-old returned home from her out-of-state hospital stay on Monday evening.
Dionne Sims, Lee's granddaughter, says the 98-year-old has been resting, reading and staying in bed.
For now, she is not doing any interviews to give her time to rest.
What they're saying
"I think one of the things she is most encouraging young people to do is to take Juneteenth, take the baton and go forward. you'll hear that, she's always said it. I think we just need to pay attention to what she said. She always said It's not a me thing. It's a we thing," said Sims.
There is one call that Lee did take.
Former vice president Kamala Harris called after she heard about her hospital stay.
What they're saying
"She had a big smile on her face, right. To think that the former vice president, would call to check in on her, really, it made us feel special. We all know that she is, but I don't think she realizes she is," Sims said.
Lee's health is leading to some changes for her Juneteenth festivities, including her Walk for Freedom on June 19.
She will still take part in the walk, but will be in a golf cart.
What they're saying
"It was always the plan to have my grandmother in a golf cart, one so we can finish in a timely manner, but it's just time," Sims said. "It is named for her but we definitely don't want to wear her out, so I think that is the name of the game, to keep her here as long as possible."
The Source
Information in this article comes from an interview with family members of Opal Lee.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
2 days ago
- Los Angeles Times
Serious liver disease is up among heavy drinkers, even without more drinking
Serious liver disease is becoming more common among Americans who drink heavily, according to a new study from Keck Medicine of USC. It's not that more people are partying with alcohol. And it's not that the drinkers are having more drinks. It's that more of the people who drink regularly are becoming sick. Over the last two decades, the share of heavy drinkers who have advanced liver scarring jumped from 1.8% to 4.3%. For women, more than 1.5 drinks per night, on average, is considered heavy drinking. For men, it's 2 drinks. 'The fact that the risk not only increased but that it more than doubled — almost tripled — is really astonishing,' said Dr. Brian P. Lee, a liver transplant specialist at Keck Medicine of USC and lead author on the study. It was published in the journal Clinical Gastroenterology and Hepatology on Wednesday. Lee said he thinks patients might dramatically change their thinking and behavior if they had this information. The increase in illness was seen especially in women, older people and those with conditions like obesity or diabetes. Three USC researchers analyzed national health data from more than 44,000 adults surveyed between 1999 and 2020 in a well-known national heath study known as NHANES. Of those, 2,474 were heavy drinkers according to the definition of the National Institute on Alcohol Abuse and Alcoholism — 20 grams of alcohol per day for women and 30 grams for men, roughly the equivalent of 1.5 and 2 drinks. They found a more than twofold increase over the two decades in significant liver fibrosis, a condition where healthy liver tissue is replaced by stiff, fibrous tissue — like a sponge hardening into leather. If left unchecked, this can eventually lead to liver failure or cancer. By comparison, non-heavy drinkers saw a much smaller increase, from 0.8% to 1.4% over the same period. This rise in liver damage is especially troubling because many people don't realize anything is wrong until the disease is advanced. 'Liver disease is silent,' Lee said. 'Most people won't, even if they have [advanced liver scarring], have any symptoms at all.' Drinking patterns did not change much over the study period. But the health profiles of heavy drinkers did. Rates of metabolic syndrome — a cluster of conditions including obesity, diabetes, and high blood pressure — increased from 26% of people, to nearly 38%. Demographics shifted too: heavy drinkers became more likely to be women, people over the age of 45, and those living in poverty. 'We're showing with this study that the picture of the American drinker is changing dramatically,' Lee said. 'You have more women who are drinking heavily, more ethnic minorities who are drinking heavily, and these are groups that are known to have a higher sensitivity to alcohol in causing liver damage.' Other factors may also be at play, said Dr. Sammy Saab, medical director of the Pfleger Liver Institute at UCLA, who was not involved in the study. People could be consuming different types of drinks, or at different times. 'Have we moved away from beer, wine, to hard cocktails? Have we moved away from drinking with food, where the food absorbs some of the alcohol you consume, versus drinking without food where alcohol is better absorbed?' Saab asked. Then there are cultural changes, he said. 'In the old days, if you drank, you'd still have to drive home, but now we've got Uber, we have Lyft,' he said, which may remove some deterrents to heavy drinking. The current definition of heavy drinking in the U.S. may actually be too lenient, Lee said, especially compared to evolving global standards. Canada, for example, now advises no more than two drinks per week to minimize health risks. 'In the U.S. right now, we consider heavy drinking to be eight drinks or more per week for women and 15 or more for men — but that's quite high,' he said. 'We've shown in prior studies that you can develop liver disease at lower quantities than the U.S. threshold.' The study's findings highlight the need to rethink long-held assumptions about alcohol-related liver disease, and Lee hopes it can be used to develop more effective screening methods for early detection. The paper raises a lot of good questions, Saab said, serving as a call to action for researchers and clinicians to better understand this increase in alcohol-associated liver disease — and how to stop it.
Yahoo
5 days ago
- Yahoo
Award winners honoured at Teesside University's graduation ceremonies
A pioneering games developer, an innovative tech entrepreneur, and a healthcare leader were honoured alongside thousands of students during Teesside University's academic awards this month. A total of 17 graduation ceremonies were held at Teesside university from Tuesday, July 8 to Wednesday, July 16, when 4,000 students celebrated their academic achievements. The ceremonies took place in the new £40 million Digital Life building, which is intended to advance teaching and research in fields such as digital media, artificial intelligence, robotics and games design for the Tees Valley and beyond. During the ceremonies, honorary degrees were bestowed on Lee Hutchinson, founder of global gaming giant Double Eleven, and Dean Benson, chief executive of e-commerce powerhouse Visualsoft. Honorary Graduate Derek Bell (Image: Judy Hume) Both are Teesside University graduates and recognised for their groundbreaking work in gaming and tech, having founded and developed their own hugely successful businesses in the region. Also honoured as an honorary graduate was Professor Derek Bell OBE, chair of the University Hospitals Tees group board. Professor Bell, who has made instrumental contributions to healthcare both regionally and nationally, was awarded an OBE in 2018 for services to Unscheduled Care and Quality Improvement. Honorary Graduate Lee Hutchinon (Image: Judy Hume) Professor Bell said: "It's a great privilege to be honoured in this way. "The University's buildings and facilities for students are just exceptional, and I can see how that attracts students from all over the world. "Teesside University's reputation continues to go up and up. "The opportunities are fantastic, along with the opportunity to take the different skills that people have learned at the University out into the wider world. "As I walk across the stage I will be thinking about what an honour it is, but also thinking about the speech I'll be making, celebrating the importance of the University within the local region, particularly in relation to health science training, but also looking to the future. "Hopefully Teesside University will get a new medical school, which I think will be a great boost to the local economy." Mr Hutchinson said: "Teesside has a special place in my heart because it was the place that gave me my degree. "It feels really good to be recognised for the work I've done in the community. "Teesside as a university is really helped by listening to the actual people around it and tailoring their courses to fit exactly with what the actual industry wants. "Having all kinds of digital industry degrees is massively beneficial for us." Speaking during the ceremony where he was awarded his honour, Mr Hutchinson added: "Thank you, Teesside University, for giving me opportunity and for investing in futures that don't yet exist. "Together, let's continue to put Middlesbrough, the North-East, and our University on the global map of creativity and impact." Mr Benson said: "The feeling I get from receiving this award is one of inspiration. "I want to be there for other people and help people related to Teesside to flourish and perhaps be a role model for other people. "Teesside University stands for excellence and an amazing education. "I've dealt with the University all through my life, studying at the University, work placement from school at the University, right the way through to being a Governor at the University and now today with the honorary doctorate, it's an absolute pleasure. "Teesside University holds a massive role within the region, it stands for everything that everyone strives and works for; its morals, its ethics, its education. "What people come out with from the University is a future. "The Digital Life building is absolutely phenomenal. "It's one of the examples of how the University has innovated. It's set the vision, it delivered the vision."
Yahoo
6 days ago
- Yahoo
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), leveraging its specialized early intervention sales force to co-promote the treatment to existing and new customers. ZILRETTA is Pacira's extended-release treatment for osteoarthritis knee pain. This agreement is expected to significantly expand access and extend reach across a large portion of the seven million intra-articular knee injections administered to patients annually in the U.S. 'This partnership embodies our 5x30 strategy of leveraging innovative, targeted collaborations that drive growth, enhance our commercial presence, and improve the patient journey with safe, effective non-opioid treatments," said Frank D. Lee, chief executive officer of Pacira BioSciences. 'With its proven long-lasting benefits and distinct mechanism of action, ZILRETTA is uniquely positioned to meet a critical need in osteoarthritis pain management, and we believe this agreement will allow us to reach even more patients across the country,' added Mr. Lee. With a significantly expanded promotional effort through a collaboration with Johnson & Johnson MedTech's early intervention sales force, which currently promotes hyaluronic acid injections for osteoarthritis knee pain, this team now has the opportunity to support individualized pain management based on patient needs and preferences. This collaboration extends the reach of ZILRETTA beyond orthopedic practices into additional physician specialties, including sports medicine, pain management and rheumatology. About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®°, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit About ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) On October 6, 2017, ZILRETTA was approved by the U.S. Food and Drug Administration as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis (OA)- related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide—a commonly administered, short-acting corticosteroid—with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase 3 trial on which the approval of ZILRETTA was based showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. Learn more at Indication and Select Important Safety Information for ZILRETTA Indication: ZILRETTA is indicated as an intra-articular injection for the management of OA pain of the knee. Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated. Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product. Warnings and Precautions: Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration. Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration: Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use. Hypersensitivity reactions: Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs. Joint infection and damage: A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute appropriate antimicrobial treatment. Adverse Reactions: The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions. Please see for full Prescribing Information. Forward-Looking StatementsAny statements in this press release about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'project,' 'should,' 'will,' 'would,' and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: '5x30', our growth and business strategy, our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation ('NOPAIN') Act, the expected cost savings and benefits of the July 2025 reduction in force and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome ('pMVL') drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the 'Risk Factors' of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the 'SEC'). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. 1 Co-Promotion Agreement between Pacira Pharmaceuticals Inc. and DePuy Synthes Sales, Inc. CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 Media Contact: Sara Marino, (973) 370-5430 in to access your portfolio
